Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

Inclusion Criteria: * Male or female (non-childbearing potential) * Body Mass Index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening * Non-smoker * Medically healthy with no clinically significant laboratory profiles, vital signs or ECGs Exclusion Criteria: * mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study * History or presence of myopathy and/or hypothyroidism. * History or presence of transaminase elevations * History or presence of hypersensitivity or idiosyncratic reaction to rosuvastatin, to other HMG-CoA reductase inhibitors, to Epanova™, to Vascepa®, or to related compounds * Known sensitivity or allergy to soybeans, fish, and/or shellfish. * Has consumed fish within 7 days prior to check-in. * Female subjects who are pregnant or lactating. * Positive urine drug and alcohol results at screening or check-in. * Positive urine cotinine at screening and check-in * Use of any drugs known to be inducers of CYP enzymes and/or P-gp * Donation of blood or significant blood loss within 56 days prior to the first dose of study medication. * Plasma donation within 7 days prior to the first dose of study medication. * Participation in another clinical trial within 28 days prior to the first dose of study medication.